Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Preclinical Development: Overview01:28

Preclinical Development: Overview

5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Drug Discovery: Overview01:26

Drug Discovery: Overview

10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K
In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

269
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
269
Drug Regulation01:25

Drug Regulation

2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

The potential of key Alzheimer's plasma biomarkers to mimic tau PET MUBADA-based disease staging.

Alzheimer's research & therapy·2026
Same author

Concordance between domain-based neuropsychological profiles and clinical phenotypes in young-onset dementia.

The Clinical neuropsychologist·2026
Same author

Clinical drug development in amyotrophic lateral sclerosis: industry-reported challenges and opportunities.

Amyotrophic lateral sclerosis & frontotemporal degeneration·2026
Same author

Amateur Soccer Heading and Acute Elevations in Blood-Based p-Tau217 and S100B.

JAMA neurology·2026
Same author

Top five Alzheimer Disease trial eligibility criteria favor men compared to women in a clinic-based cohort.

The journal of prevention of Alzheimer's disease·2026
Same author

Sex differences in documented clinical features of memory clinic patients: a natural language processing study.

Cerebral circulation - cognition and behavior·2026

相关实验视频

Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K

药物开发 药物开发

Lieza G Exalto1,2, Siti S Syaziyah3, Xiaotian T Fang1

  • 1Julius Clinical, Zeist, Netherlands.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 25, 2025
PubMed
概括
此摘要是机器生成的。

女性不太可能符合阿尔茨海默氏症的条件.

更多相关视频

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

446

相关实验视频

Last Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K
In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

446

科学领域:

  • 神经学 神经学
  • 临床试验 临床试验
  • 医学研究 医学研究

背景情况:

  • 阿尔茨海默病 (AD) 药物试验往往缺乏相对于全球痴呆症人口的女性参与.
  • 行业利益相关者致力于包容性试验,重点关注参与和招聘.
  • 本研究调查了试验设计,特别是资格标准如何影响基于性别的参与率.

研究的目的:

  • 分析常见的阿尔茨海默病临床试验资格标准对参与资格的男女比例的影响.
  • 确定特定的标准,不成比例地影响妇女在AD试验中的资格.

主要方法:

  • 从 563 个注册在 clinicaltrials.gov.gov 上的二期和三期AD 药物试验中提取了资格标准.
  • 根据前5个最常见的纳入标准,手动注释了113项试验.
  • 在阿姆斯特丹阿尔茨海默氏症中心对一组被诊断患有阿尔茨海默氏症或轻度认知障碍 (MCI) 的男性和女性连续应用了这些标准.

主要成果:

  • 排名前五的标准包括:没有其他中枢神经系统 (CNS) 疾病,护理人员参与,迷你精神状态检查 (MMSE) 评分范围 (24-30),没有研究程序的禁忌,年龄范围 (55-85).
  • 将这些标准连续应用于3835名患者 (48%为女性),女性的资格明显下降.
  • 最终的资格是男性31%,女性16%,主要是由于MMSE得分较低,女性缺乏护理人员的可用性.

结论:

  • 在阿尔茨海默氏症临床试验中常用的资格标准导致女性的资格率低于男性.
  • 呈现时MMSE得分较低和护理人员可用性减少似乎是导致这种差异的关键因素.
  • 试验设计应考虑这些因素,以促进更公平地将女性纳入AD药物试验.